MedWatch

Analyst: Bavarian Nordic has an attractive Covid-19 vaccine candidate

New data confirms Bavarian Nordic’s Covid-19 vaccine’s booster potential, as the candidate increased neutralizing antibody levels enough to protect against the virus.

Photo: Rune Aarestrup Pedersen/IND

Additional data from Bavarian Nordic’s phase II study of its Covid-19 vaccine is positive, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

”In our opinion, Bavarian Nordic has a very attractive candidate, which could be used in a potential booster market going forward. On top of this, in connection with the approval process, Bavarian Nordic isn’t required to demonstrate the effect of ABNCoV2 against a specific Covid-19 strain like Omicron, which we deem positive,” Løntoft Hansen writes in a note.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs